Fellowship Details Requirements

Top

Fellowship Details & Requirements

A group of infectious diseases fellows posing for a photo

In 1974 Herbert L DuPont, M.D., chair of Infectious Diseases at McGovern Medical School (then known as the UTHealth Science Center at Houston Medical School) and Gerald P Bodey, M.D., chair for Infectious Diseases at MD Anderson, agreed to start a combined ID fellowship program that offered rotations at clinics affiliated with MD Anderson, Memorial Hermann Hospital and McGovern Medical School. Two tracks were offered, the traditional track and the immunocompromised track. Fellows in the immunocompromised track spent most of the time at MD Anderson and rotated in the general ID service at McGregor Medical School.

In 1990, the program expanded to include rotations at the Lyndon B Johnson General Hospital. By 2005, a similar agreement with Baylor College of Medicine was established, offering training in both the traditional and immunocompromised tracks. In 2019, MD Anderson launched a nonstandard training (NST) program with UTHSC in Transplant and Oncology with approval of the Texas Medical Board. A few years later in 2024, fellows in the MD Anderson NST program began rotating in the immunocompromised service at The Houston Methodist Hospital, which offers exposure to many patients undergoing solid organ transplantation.

MD Anderson is the largest comprehensive cancer center in the country and is located in the largest medical center in the world (Texas Medical Center). Fellows rotating at MD Anderson acquire ample clinical experience rotating in the difference consult services and pursue research training opportunities in infectious diseases following ACGME requirements. Our clinical and basic science faculty provide clinical and research support and have successfully mentored trainees that are now full-time clinicians, clinician investigators, clinician educators or physician scientists.

Eligibility, Prerequisites & Application Process

Infectious Diseases fellows are invited for interviews by applying to one of our joint programs. Prospect applicants can also review our Graduate Medical Education office requirements.

Program Goals & Objectives

Our combined Infectious Diseases fellowship program have the following goals and objectives aligned to the six core ACGME competencies:

Medical Knowledge:

Acquire proficiency and expertise in the recognition, diagnosis, and management of common and unusual infectious diseases in immunocompromised and cancer patients
Recognize and manage infectious and non-infectious complications associated with commonly used immunosuppressive drugs, chemotherapeutic agents, targeted therapies and adoptive cellular therapies
Understand the current cancer treatment modalities that have implications in the increased risk, diagnosis and management of infectious diseases
Develop proficiency in the interpretation of antimicrobial susceptibility testing and molecular based diagnosis of infectious agents
Appropriate use of antimicrobial agents according to antimicrobial stewardship guidance. Understand the importance of proper dosing and recognize and manage antimicrobial related toxicities
Recognize and apply strategies for prevention of infections, including antimicrobial prophylaxis indications, timing and duration

Patient care:

Conduct thorough medical histories and physical exams focused on infectious diseases
Develop comprehensive diagnostic and therapeutic management plans
Recognize and treat infectious complications in cancer patients across various stages of care
Effectively order and interpret relevant diagnostic tests

Interpersonal and communication skills:

Learn and refine how to communicate sensitively and effectively with patients and families of cancer patients with infectious diseases
Demonstrate cooperative team building with all members of the consulting team including nurses, coordinators, data managers and physicians/surgeons

Professionalism:

Interact professionally towards patients, families, colleagues and all members of the health care team
Acquire the ability to display an appreciation of the social context of illness

Practice base learning:

Refine the management of infections, and recognize medical, social, and ethical limitations of cancer patients in the oncology and the palliative care service
Describe and demonstrate knowledge of fundamental resources including the AST transplant ID guidelines, evidence-based medicine databases and additional guidelines from other critical sources
Demonstration of these resources directly in patient care and in case-based discussions with transplant ID faculty

Improvement and systems-based practice:

Acquire and improve skills in critical analysis of clinical literature and conducting research
Expected to work with the service requesting the consultation to assure that care for the patient��s medical needs is properly coordinated with care being delivered by the primary service
Expected to integrate knowledge learned through participation in ward rounds, teaching conferences and other educational activities into their practice
Consider the cost-effectiveness of diagnostic, prevention and treatment strategies when selecting such strategies for patients, particularly as it relates to exercising antibiotic stewardship
Refine strategies for prevention of infections and infection control measures in this cancer population

Program Structure & Curriculum

Program duration: Two years

Patient care requirement: At least 12 months to fulfil the educational requirements of the American Board of Internal Medicine

Introductory month: Introductory lectures at the Microbiology laboratory and Antimicrobial Stewardship

Clinical rotations:
Four-week rotations at MD Anderson and across affiliated hospitals at UTHSC and BCM. Fellows spend at least a month in each one of our consult teams, consisting of 1-2 fellows, 1-2 Advanced Practice providers, 1 ID clinical pharmacist and an ID faculty attending.

The Infectious Diseases Consultation services are:

ID Hospital Medicine
ID Surgical Oncology
ID Leukemia
ID Stem cell Transplant
ID Lymphoma, myeloma, and targeted cellular therapy

Fellows are responsible for evaluating all patients on the Consult service. Fellows have the opportunity to select elective rotations in the second year of fellowship.

Clinical conferences:
All fellows actively participate and attend department and shared clinical conferences:

Tuesday 12:30 p.m.: journal club session, research presentation session
Wednesday 8 a.m. ID clinical conference: ID department conference where clinical cases are presented by fellows and discussed with all faculty, ID pharmacists, APPs and clinical microbiologists
Wednesday 12 p.m. Texas Medical Center ID City Wide Conference: Presentation of most interesting cases from all hospital facilities followed by a rich educational wide group discussion
Thursday 1 p.m. ID Core Curriculum conference: ID board-oriented conference

Outpatient clinic rotations:
Fellows participate in continuity clinics at the respective programs and may also choose to rotate in our General ID, Transplant ID and Hepatitis outpatient clinics.

Research:

Fellows select their research mentor during the first year of fellowship
Fellows have 6-12 months of research experience which can be tailored to personal goals and objectives
All fellows present their research in national and international Infectious Diseases society meetings and publish in peer reviewed journals

Supervision and Evaluation:
Supervision:

All fellows are under direct supervision of attending faculty.
The program has a progressive and incremental increase in patient care responsibilities as the fellow demonstrates the skills outlined in the competency-based goals and objectives.

Evaluation:

Fellows are evaluated at the end of each clinical rotation by attending faculty according to the ACGME 6 core competencies.
Biannual evaluations by the clinical competence committee.
Periodical meetings with program director and research mentor to discuss progress and career and research goals.

On-call duties:

Weekdays, after-hours: All rotating fellows expected to attend calls at home if paged by consulting team.
Weekend call: All rotating fellows alternate in-hospital weekend calls.
Other Educational Opportunities: Participation in Quality Improvement, Antimicrobial Stewardship and Infection Control programs according to career goals.

Program Faculty & Leadership

Infectious Diseases Faculty

Professor and Head of Division of Internal Medicine

Dr. Tweardy is a graduate from Case Western Reserve University Infectious Diseases Fellowship program. His overall research interests focus on understanding and modulating the host damage response to microbial and other injuries to treat disease. His basic research interests over the past 30 years have centered on cytokines and cytokine signaling. In particular, he has focused on the second messenger�� signal transducer and activator of transcription (STAT) 3 �� which is critical in the signal transduction pathway of over 40 cytokines. Work by his group and others has shown that STAT3 makes essential contributions to chronic inflammation, fibrosis and cancer. The clinical research interests of Dr. Tweardy are focused on the use of a small-molecule STAT3 inhibitor, TTI-101, identified in his lab to treat and/or prevent chronic inflammation, fibrosis and cancer.

Professor, Department Chair and Director of the Clinical Virology Research program

Dr. Chemaly is a graduate from the Cleveland Clinic Infectious Diseases Fellowship program. He is a world leading researcher in virology. His interests include studies on epidemiology, severity, prognosis, prevention and treatment of respiratory viral infections in immunocompromised cancer patients and in prevention of health care-associated infections. He is the founder and past chair of the Transplant Infectious Diseases Interest Group of the American Society of Bone Marrow Transplantation. He also is a member of the writing committee of the ASBMT guidelines and the European Committee for infections in Leukemia (ECIL 8); executive member of the council for the International Immunocompromised Host Society (ICHS); and Chair for the working group on respiratory viruses (ESGREV) of the European Society for Clinical Microbiology and Infectious Diseases (ESCMID). ?

Professor and Fellowship Program Director

Dr. Okhuysen is a graduate from the UTHealth Houston Science Center McGovern Medical School/MD Anderson Infectious Diseases Fellowship Program (��94). The Okhuysen laboratory research interests include the identification, epidemiology, pathogenesis, host immune response, treatment and prevention of gastrointestinal infections, including diarrheagenic Escherichia coli, Cryptosporidium, Clostridioides difficile in immunocompromised and cancer patients. Dr. Okhuysen served on the board of scientific advisors for the CDC and has been an advisor to NASA. He has served on the Infectious Diseases Society of America Publications and Research Awards Committees and was awarded the Oswald Avery Award for Early Achievement by the Infectious Diseases Society of America in 2007. He also is a past director of the NIH NCRR-funded General Clinical Research Center at UTHealth Houston/Memorial Hermann Hospital and co-lead the joint UTHealth Houston McGovern Medical School NIH CTSA-funded Center for Clinical and Translational Services. He has repeatedly received the best teacher award from fellows in the McGovern and BCM fellowship programs.

Assistant Professor and Fellowship Associate Program Director

Dr. Yepez is a graduate from the UTHealth Houston Science Center (UTHSC) McGovern Medical School/MD Anderson Infectious Diseases Fellowship Program with additional advanced training in Transplantation Infectious Diseases at UTHSC. He serves as the associate director of the Antibiotic Stewardship team and is an active member of the Pharmacy and Therapeutics Committee. Dr. Yepez��s research interests are infections in patients with hematological malignancies, including evaluation of reactivation or onset of new infections in cancer and immunocompromised patients exposed to new targeted cancer therapies and immunotherapy; gastrointestinal infections, including Clostridioides difficile infection; and viral hepatitis, including evaluation and treatment, risk of reactivation and safety of antiviral therapy. He also works at the viral hepatitis clinic and collaborates in multiple research projects.

Professor and Clinical Vice-Chair

Dr. Adachi is a graduate from the UTHealth Houston Science Center McGovern Medical School/MD Anderson Infectious Diseases Fellowship Program and is a past associate director of the infectious diseases fellowship at MD Anderson Cancer Cener and Baylor College of Medicine. Dr. Adachi is the clinical service director of Infectious Diseases in Leukemia and the director of the division��s quality improvement projects. He is involved in several research projects related to cancer patients. He actively mentors fellows, midlevel providers, nurses and junior Faculty participating in the Clinical Safety and Effectiveness course, a yearly QI (Quality Improvement) training course offered at MD Anderson that enhances training in QI and allows participants to apply for the Certificate in Medical Quality.

Professor

Dr. Ariza is a graduate from the University of Miami��s Jackson Memorial Hospital Infectious Diseases fellowship program, with subsequent third-year training in Transplant Infectious Diseases at the Mayo Clinic in Rochester, Minn. Dr. Ariza is the clinical service director of Infectious Diseases in the Hematopoietic Stem Cell Transplant consult service. Her clinical and research interests include the management of infections in stem cell transplant recipients with an emphasis on viral respiratory and vaccine-preventable infections, as well as patients undergoing CAR-T and other adoptive cellular therapies.

Assistant Professor

Dr. Bharadwaj is a member of Dr. Tweardy��s Laboratory, which focuses on understanding and modulating the host damage response to microbial and traumatic injury to treat disease. His overall interest is in the role of IL-6/STAT3, IFN/STAT1/2 signaling in cancer initiation, progression and immune modulation. Dr. Bharadwaj is focused on delineating the exact roles of these pathways, especially a group of Interferon Stimulated Genes, the IFN-related DNA damage resistance signature (IRDS) gene set, in conferring chemo-radio resistance, and metastatic abilities to head and neck squamous cell carcinoma (HNSCC) cells, as well as how the HNSCC-associated viruses, e.g. HPV (human papillomavirus), HCV (hepatitis C virus), modulate the STAT1/3 pathways to affect disease severity in these patients. Also, he is actively involved in preclinical research involving co targeting of STAT3, a known immune modulatory agent.

Professor

Dr Chaftari is a graduate from Saint Joseph University, Faculty of Medicine in Beirut, Lebanon. She completed an anesthesia residency program at the American University of Beirut in Lebanon, Internal Medicine Residency training at Staten Island University Hospital, in Staten Island, N.Y., a fellowship in Geriatrics at Tulane University Medical and postdoctoral training on Infectious Diseases at MD Anderson. She oversees the daily operation of Dr. Issam Raad��s clinical research team and the conduct of clinical studies. She leads several clinical research trials at the institution and collaborates in multiple multicenter
clinical research projects sponsored by industry and NIH. Her clinical research areas of interest include infectious diseases complications in cancer patients, such as central line-associated bloodstream infections, and neutropenic fever. Other areas of interest include novel antimicrobial therapies and biomarkers of
sepsis.

Associate Professor

Dr. Garnes is a graduate from the Baylor College of Medicine Infectious Diseases Fellowship Program. Dr. Garnes is dually boarded in adult and pediatric infectious diseases. She is the clinical service director for the pediatric infectious diseases consult service, director of the outpatient parenteral antimicrobial therapy program and director of the Antimicrobial Stewardship Program. Her research interests include infections in pediatric immunocompromised and cancer patients.

Professor

Dr. Granwehr is a graduate from �鶹ӳ�� Medical Branch Infectious Diseases Fellowship program. He previously has served as site director and associate director of the MD Anderson UTHSC and BCM Infectious Diseases combined fellowship programs. He is the clinical director of the Infectious Diseases Hospital Medicine consult service. His research interests include the early identification of HIV in patients with newly diagnosed cancer and the oncologic complications of HIV. Dr. Granwehr is also interested in the management of HIV and hepatitis C infection in patients receiving cancer chemotherapy. Dr. Granwehr received the 2017-18 Best Infectious Diseases Fellowship Teacher Award from the BCM fellows.

Professor

Dr. Ray Hachem is director of the Infectious Disease Training & Observership program in the Department of Infectious Diseases, Infection Control & Employee Health at MD Anderson. His research interests focus on pathophysiology and management of diseases in humans caused by bacterial and fungal pathogens. He has been involved in conducting many clinical trials, as well as basic and translational research that pave the way to multiple studies to improve the care of cancer patients with infections. He has worked extensively on clinical trials pertaining to invasive fungal infections and device related infections. He has been involved in over 20 clinical trials or laboratory studies, including several animal models. Dr. Hachem served as the chairman of the Division of Internal Medicine Research Committee. He also serves on the Institutional Review Board, the Institutional Research Grant (IRG) Committee, and the Ad Hoc Committee of the Infection Control Committee for the Prevention of Fungal Infections.

?Assistant Professor

Dr. John is a graduate from the Cleveland Clinic Internal Medicine and Infectious Diseases Fellowship Program. His clinical expertise lies in mycology, emphasizing diagnostics, therapeutics, and stewardship. Dr. John holds the position of chair at the department's pivotal Wednesday clinical conference. His research focuses on mycology and breath metabolomics. He actively contributes as a member of the "Young MSG" within the Mycosis Study Group, the consortium for clinical metagenomics in infectious diseases and serves on the ID Metabolites/Direct MALDI Work group for the American Society of Transplantation Biomarker Consensus Conference.

Assistant Professor

Dr. Kasembeli is a member of Dr. Tweardy��s Laboratory, which focuses on understanding and modulating the host damage response to microbial and traumatic injury to treat disease. Dr. Kasembeli��s research is centered on the development of potent and selective inhibitors of STAT3 activity to target cancer and diseases marked by chronic inflammation. He also studies molecular mechanisms of a rare primary immune deficiency syndrome linked to loss of function of STAT3. He is primarily interested in the modulation of the activity of STAT3 with the goal of reducing its activity in diseases in which it is hyper-activated, such as cancer, and enhance its activity in diseases marked by loss of function of STAT3, such as autosomal dominant hyper IgE syndrome (AD-HIES).

Associate Professor

Dr. Khawaja completed his Internal Medicine and Infectious Diseases training at McGovern Medical School UTHealth Science Center at MD Anderson. His research scope is clinical studies focused on viral infections in patients with hematologic malignancies and recipients of cellular therapy. He leads multiple
interventional trials to treat and prevent CMV and respiratory viral infections (including COVID-19). In addition, he heads multiple database studies to measure infectious complications in recipients of novel therapies for hematologic malignancies, such as CAR (Chimeric Antigen Receptor) T cell therapy.

Professor

Dr. Kontoyiannis is the Robert Hickey Endowed Chair, a professor in Infectious Diseases, and the deputy head of research in the Division of Internal Medicine. Dr. Kontoyiannis is a graduate from Massachusetts General Hospital��s Harvard Medical School Infectious Diseases Fellowship program. He is a leading world researcher in mycology, studying the pathogenesis of invasive fungal infections (IFIs) and the development of novel therapeutic strategies against these devastating infections. Other areas of interest include antifungal resistance, novel diagnostics, delivery systems and fungal pharmacology. For more than 25 years, the Kontoyiannis laboratory and clinical research program has made significant contributions to broaden our understanding and knowledge of IFIs, the immunopathology of IFIs, activity of conventional and novel antifungal compounds and combination therapy, including development of novel experimental Drosophila and mice models. Dr. Kontoyiannis has been member of the writing committee for aspergillus treatment guidelines for Infectious Diseases Society Of America and the chair of the treatment guidelines for aspergillosis and rare molds for American Society of Transplantation and Cellular Therapy, president-elect of the Mycoses Study Group (2024-2026), past president of the International Immunocompromised Host Society and leader of the European Confederation for Medical Mycology (ECMM) Diamond Excellence in Mycology Center at MD Anderson. He is a recipient of many national and international prestigious awards for his research in mycology and a member of honorific societies such as Association of American Physicians, American Medical Association and American Association for the Advancement of Science.

Professor

Dr. Mulanovich has served as Infectious Diseases department chair ad interim, past clinical vicechair. Dr. Mulanovich is a graduate from the University of Alabama at Birmingham Infectious Diseases Fellowship Program. He conducts research in immunocompromised and cancer patients. His clinical research interests include infections in patients with hematologic malignancies and in recipients of hematopoietic stem cell transplants. He was Director of the Antimicrobial Stewardship Program. In multiple occasions, he received the outstanding teaching award in Infectious Diseases by UTHSC and BCM.

Professor

Dr. Raad has previously served as department chair of Infectious Diseases. He is a graduate from the University of Florida Infectious Diseases fellowship program. Dr. Raad is considered one of the world��s leading experts in health care-related infections and infections in cancer. His research includes development of innovative antimicrobial central venous catheters and devices that have reduced the risk of bloodstream infections worldwide by more than 12-fold. In the most recent CDC Guidelines (2011), his innovations (including the antimicrobial catheters and maximal sterile barrier) have been recommended at the highest level (Category 1A) for the prevention of health care associated bloodstream infections, which have become the standard of care. He has expanded his research to develop other antimicrobial coated devices, including urologic and breast implants, ventriculostomy and drainage catheters. He has been awarded as distinguished educator at MD Anderson in 2019 and The Society for Healthcare Epidemiology of America��s Mentor Scholar award in 2015.

Associate Professor

Dr. Robinson is a member of Dr. Tweardy��s Laboratory, which focuses on understanding and modulating the host damage response to microbial and traumatic injury to treat disease. Dr. Robinson is actively involved in studying the role of substance P, a pro-inflammatory neuropeptide and pain transmitter in various cancers, including inflammation-associated colon cancer and triple negative breast cancer.

Professor

Dr. Shelburne is a graduate from the Baylor College of Medicine/MD Anderson Infectious Diseases Fellowship Program. Dr. Shelburne is the deputy chair for scholarly activity in the department, director for the Genomic Infectious Diseases research group at MD Anderson, leading member for the steering committees for antibiotic resistance, Gulf Coast Consortium on Antimicrobial Resistance and Microbiome working groups. He is also a member of the Antimicrobial Resistance Peer Reviewed Medical research program,
a medical research program at the U.S. Department of Defense directed by
Congress. His research team focuses on understanding the molecular basis
of bacterial infections in humans and the molecular basis underlying bacterial
antimicrobial resistance (AMR). Dr. Shelburne is the head of the immunocompromised section of the NIH Funded Antibiotic Resistance Leadership Group and has published on AMR mechanisms in bacteria ranging from Staphylococcus epidermidis to Escherichia coli. The Shelburne laboratory seeks to understand how variation in bacterial virulence impacts clinical outcomes, using group A streptococcus (GAS) as a model organism. Specific projects include unraveling the complex regulation of virulence by the two-component regulatory system CovRS in GAS, identifying mechanisms driving emergence of new GAS clones, and understanding how resistance to oxidative stress impacts disease occurrence. He also received the outstanding clinical research mentor at MD Anderson School of Health Professions in 2019.

Assistant Professor and Chief Infection Control Officer

Dr. Spallone is a graduate from the Baylor College of Medicine/MD Anderson Infectious Diseases Fellowship Program. Dr. Spallone is the chief infection control officer at MD Anderson and our department's patient quality safety officer. Dr. Spallone��s research interests include emerging pathogens, viral infections, and infection control measures in immunocompromised populations. Under the mentorship of Dr. Roy Chemaly, Dr. Spallone assists in several clinical trials, including investigational antiviral agents for respiratory viral pathogens and mapping changes in the respiratory microbiome/virome composition to predict clinical outcomes in hematopoietic cell transplantation recipients and patients with leukemia. She is the primary investigator on environmental surface disinfection studies piloting hand-held UV devices and a co-mentor/collaborator with Dr. Sam Shelburne on utilizing Oxford Nanopore Technology third generation sequencing for rapid identification of hospital-acquired infections in health care settings.

Assistant Professor

Dr. Srinivasan is a graduate from the Baylor College of Medicine/MD Anderson Infectious Diseases Fellowship Program, and she also completed a secondary fellowship in Hospital Epidemiology and Infection Control at Stanford University Infectious Diseases and Geographic Medicine Fellowship Program. She is the medical director of Employee Health at MD Anderson. Her interests include the mitigation of biohazards, infection prevention and occupational health in higher education and research institutions.

Associate Professor

Dr. Szvalb is a graduate from the Baylor College of Medicine/MD Anderson Infectious Diseases Fellowship Program and past member of Faculty Senate and Pharmacy and Therapeutic Committee. Dr. Szvalb is also a member of Dr. Kontoyiannis clinical research group. His research interests include Pneumocystis jirovecii pneumonia, invasive fungal infections, and device-related infections such as percutaneous nephrostomy tubes, Foley catheters, and Ommaya reservoirs.

Professor

Dr. Torres is an Ashbel Smith Distinguished Professor and Adjunct Professor at the Department of Gastroenterology, Hepatology, and Nutrition. Dr. Torres is a graduate from the UTHealth Houston Science Center McGovern Medical School/MD Anderson Infectious Diseases Fellowship Program. He is the founder and director of the Hepatitis C virus (HCV) clinic at MD Anderson, the first established clinic in the U.S., and likely in the world, devoted to managing HCV in cancer patients. He is a member of numerous national committees for professional societies such as American Association for the Study of Liver Diseases, European Association for the Study of the Liver, Infectious Diseases Society of America and European Society of Clinical Microbiology and Infectious Diseases. He is the Chair of the AASLD Special Interest Group on HCV. His research interest is to facilitate translational research in the prevention, detection, and treatment of HCV in patients with cancer and hematopoietic cell transplantation. His work addressed the fact that HCV is a neglected condition in cancer patients. Additionally, he has discovered new associations between HCV and other cancers (e.g., Head and Neck cancers). He has also documented the effectiveness, benefits and safety of antiviral therapy in HCV-infected patients with cancer including those with hepatocellular carcinoma and B-cell non-Hodgkin lymphoma. He is the principal investigator for research grants on HCV received from the NIH/NCI and pharmaceutical companies (investigator-initiated studies). Dr. Torres lectures widely nationally and internationally on viral hepatitis in cancer patients. Dr. Torres' work has significantly impacted the standard of care for HCV-infected cancer patients.

Professor

Dr. Viola is a graduate from the Baylor College of Medicine Infectious Diseases Fellowship Program. Dr. Viola is the director of the outpatient clinic and the Solid Cancer and Surgical Related Infectious Diseases services. His main research interests are the prevention, diagnosis and treatment of medical device-related infections in immunocompromised and cancer patients, such as: cardiac implantable electronic device, intravenous catheters, breast tissue expanders after mastectomy, nephrostomy tubes and Ommaya reservoirs.

Assistant Professor

A member of Dr. Kontoyiannis�� lab, Dr. Wurster��s research interests are the immunopathology and immunotherapy of fungal infections, innovative mammalian models and mini-host models of invasive mycoses, and translational research as it relates to the diagnosis and treatment of fungal infections. Specifically, he is studying immune checkpoint inhibitors and other immune therapeutics as experimental treatments in murine models of invasive mold infections. Furthermore, he has been a driving force in the development of a high-throughput larval zebrafish model to study interactions of pathogenic fungi with epithelial barriers. He has also developed automated image analysis algorithms to dissect the morphogenesis and proliferation of molds during antifungal (combination) therapy and immune cell encounters. Dr. Wurster has been the recipient of the Division of Internal Medicine Research & Quality Improvement Award 2020 and Cyrus Scholar Award 2021.

Support Staff:

Ms. Lauren Sutton. Program Manager. LMSutton1@mdanderson.org
Ms. Gabrielle E King. Program Coordinator. geking1@mdanderson.org

Clinical Microbiology Department

three people in a clinical microbiology lab looking at a specimen

From left to right: Brenda Snider, clinical microbiology lab coordinator; Kenya Ellis, laboratory supervisor; and Micah Bhatti, M.D., Ph.D., assistant professor, Laboratory Medicine

MD Anderson is supported by a state-of-the-art diagnostic clinical microbiology laboratory, led by Dr. Jeffrey Tarrand, Dr. Xiang-Yang Han, and Dr. Micah Bhatti. This advanced laboratory provides comprehensive services for the identification and isolation of viral, bacterial, fungal, and protozoan parasites. The laboratory uses innovative technologies, including multiplexed nucleic acid amplification tests for syndromic diagnosis, real time antimicrobial susceptibility testing using accelerate pheno? and identification of pathogens using matrix assisted laser desorption/ionization time of flight mass spectrometry (MALDI-TOFF MS). Quantitative PCR for common viral agents is performed on site.

During the month of July, first year fellows rotate in the clinical microbiology lab.

Infectious Diseases Clinical Pharmacy Specialists

From left to right: Kevin Lin, Pharm.D., Alex Stabler, Pharm.D., Jovan Borjan, Pharm.D., Nancy Vuong, Pharm.D., Joshua Hendrickson, Pharm.D., Kelsey Olson, Pharm.D., and Meghan Kamath, Pharm.D.

The Infectious Diseases (ID) clinical pharmacists are integral members of the ID team at MD Anderson. They play a crucial role in the daily clinical management of patients with infectious diseases and contribute significantly to antimicrobial stewardship efforts.

Key Responsibilities:

Clinical Support: Provide expert guidance on the management of infectious diseases.

Antimicrobial Stewardship: Review positive blood cultures, HIV cases, and restricted antimicrobial orders, assist with outpatient parenteral antimicrobial therapy and monitor antimicrobial use across the institution.

Collaboration: Work closely with ID faculty and fellows to develop and implement research and quality improvement projects aimed at optimizing antimicrobial utilization and reducing inappropriate prescribing.

The ID clinical pharmacists also oversee their own PGY2 Infectious Diseases Clinical Pharmacy Residency Program, fostering the next generation of experts in this vital field.

Infection Control

A collage of photos with individuals wearing masks

The goal of the Infection Control team at MD Anderson is to prevent, detect, monitor and contain potential infectious disease threats to our patients, visitors and staff. Operating under the Chief Safety and Quality Office, the team works in close collaboration with Dr. Amy Spallone, Chief Infection Control Officer.

Key Functions:

Prevention: Implement strategies to prevent infectious diseases transmission and outbreaks
Detection and Monitoring: Continuously monitor and detect potential infectious threats
Containment: Swiftly respond to and contain infectious disease incidents

Collaboration:

Patient Care: Fellows work closely with the Infection Control team while caring for patients.
Research and Quality Improvement: Fellows can opt to engage in research and quality improvement projects, collaborating with Infection Control to enhance patient safety and care standards.

The Gerald P. Bodey, M.D. Infections in the Immunocompromised Host Clinical Elective

We offer a one-month clinical elective rotation for fellows in ACGME-accredited Infectious Diseases Fellowship Programs in the U.S. who would like to gain in-depth clinical experience in the diagnosis and treatment of infections in immunocompromised and cancer patients. Interested fellows can apply by email to Dr. Pablo Okhuysen at PCOKhuysen@mdanderson.org. Programs interested in sending fellows to MD Anderson for this elective require a Letter of Agreement (LOA) with MD Anderson. For details on establishing educational agreements, please contact Lauren Sutton at LMSutton1@mdanderson.org.

U.S. Medical Student and Resident Rotations

One-month clinical electives are available to U.S. medical students and internal medicine residents in ACGME accredited institutions. As with fellowship positions, a LOA is required between institutions. For additional information, contact Gabrielle King at GEKing1@mdanderson.org

International Medical Students, Residents, and Fellows

International visitors can apply to be visiting observers at our institution. For additional information, contact Gabrielle King at GEKing1@mdanderson.org

Trainee Success & Program Outcomes

Our combined fellowship program maintains a 100% board pass rate in the ABIM Infectious Diseases board examination.

All fellows publish an original research paper in a peer reviewed journal, and present a poster, abstract or oral presentation at a national or international Infectious Diseases conference meetings.

Recent graduates include faculty at the following academic institutions

MD Anderson Cancer Center
McGovern Medical School �C �鶹ӳ�� Health Science Center at Houston
Baylor College of Medicine
Houston Methodist Hospital
University of Texas Southwestern
Moffitt Cancer Center
University of Oklahoma College of Medicine
University of Kansas
LSU-Shreveport
University of South Florida
Marshall University School of Medicine, West Virginia
Washington U, St Louis
Fujita Health University, Japan
University of Arizona
University of Illinois College of Medicine
University of Nebraska
Indiana University School of Medicine
Medical College of Georgia. Augusta University
Emory University
Brown University

Fellow & Faculty Publications

2018

Alvarez RH, Bechara RI, Naughton MJ, Adachi JA, Reuben JM: . Oncologist 2018, 23(6):660-669.
Andrianaki AM, Kyrmizi I, Thanopoulou K, Baldin C, Drakos E, Soliman SSM, Shetty AC, McCracken C, Akoumianaki T, Stylianou K et al: Nat Commun 2018, 9(1):5015.
Andrianaki AM, Kyrmizi I, Thanopoulou K, Baldin C, Drakos E, Soliman SSM, Shetty AC, McCracken C, Akoumianaki T, Stylianou K et al: Nat Commun 2018, 9(1):3333.
Angelidakis G, Hwang JP, Dandachi D, Economides MP, Hosry J, Granwehr BP, Torres HA: J Viral Hepat 2018, 25(9):1102-1104.
Angelidakis G, Sturgis EM, Economides MP, Jiang Y, Torres HA: Oral Oncol 2018, 85:103-105.
Ariza-Heredia EJ, Chemaly RF: CA Cancer J Clin 2018, 68(5):340-355.
Ariza-Heredia EJ, Chemaly RF, Shahani LR, Jang Y, Champlin RE, Mulanovich VE: Transpl Int 2018, 31(6):639-648.
Azzi JM, Kyvernitakis A, Shah DP, El Haddad L, Mahajan SN, Ghantoji SS, Heredia-Ariza E, Chemaly RF: J Antimicrob Chemother 2018, 73(11):3162-3169.
Batista MV, El Haddad L, Chemaly RF: Curr Opin Infect Dis 2018, 31(6):542-552.
Castillo P, Wright KE, Kontoyiannis DP, Walsh T, Patel S, Chorvinsky E, Bose S, Hazrat Y, Omer B, Albert N et al: Mol Ther Methods Clin Dev 2018, 9:305-312.
Chaftari AM, Hachem R, Jiang Y, Shah P, Hussain A, Hamal ZA, Yousif A, Jordan M, Michael M, Raad I: Infect Control Hosp Epidemiol 2018, 39(6):727-729.
Chemaly RF, Clark TW: Curr Opin Infect Dis 2018, 31(6):512-513.
Dadwal SS, Kontoyiannis DP: . Expert Rev Mol Diagn 2018, 18(10):845-854.
Dandachi D, Hassan M, Kaseb A, Angelidakis G, Torres HA: J Hepatocell Carcinoma 2018, 5:81-86.
Dandachi D, Wilson Dib R, Fern��ndez-Cruz A, Jiang Y, Chaftari AM, Hachem R, Raad I: Ann Med 2018, 50(8):713-720.
DebRoy S, Li X, Kalia A, Galloway-Pena J, Shah BJ, Fowler VG, Flores AR, Shelburne SA: Microb Genom 2018, 4(11).
Dib RW, Hachem R, Chaftari AM, Raad I: Mediterr J Hematol Infect Dis 2018, 10(1): e2018028.
Dib RW, Hachem RY, Chaftari AM, Ghaly F, Jiang Y, Raad I: . BMC Infect Dis 2018, 18(1):656.
Economides MP, Amit M, Mahale PS, Hosry JJ, Jiang Y, Bharadwaj U, Sturgis EM, Torres HA: Cancer 2018, 124(5):960-965.
El Haddad H, Chaftari AM, Hachem R, Chaftari P, Raad, II: Clin Infect Dis 2018, 67(6):971-977.
Fern��ndez-Cruz A, Magira E, Heo ST, Evans S, Tarrand J, Kontoyiannis DP: J Clin Microbiol 2018, 56(10).
Folan SA, Marx KR, Tverdek FP, Raad I, Mulanovich VE, Tarrand JJ, Shelburne SA, Aitken SL: Open Forum Infect Dis 2018, 5(7): ofy167.
Foolad F, Aitken SL, Chemaly RF: Expert Rev Clin Pharmacol 2018, 11(10):931-941.
Galloway-Pe?a J, DebRoy S, Brumlow C, Li X, Tran TT, Horstmann N, Yao H, Chen K, Wang F, Pan BF et al: PLoS One 2018, 13(12): e0207897.
Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, Prieto PA, Vicente D, Hoffman K, Wei SC et al: Science 2018, 359(6371):97-103.
Granwehr BP: Ann Intern Med 2018, 169(12): Jc63.
Hachem R, Kanj S, Hamerschlak N, Saad H, Assir FF, Mori N, Jiang Y, Ghaly F, Chaftari AM, Raad, II: Expert Rev Med Devices 2018, 15(6):461-466.
Hammerstrom AE, Lombardi LR, Pingali SR, Rondon G, Chen J, Milton DR, Chemaly RF, Champlin RE, Gulbis A, Ciurea SO: Biol Blood Marrow Transplant 2018, 24(2):353-358.
Holland TL, Raad I, Boucher HW, Anderson DJ, Cosgrove SE, Aycock PS, Baddley JW, Chaftari AM, Chow SC, Chu VH et al: Jama 2018, 320(12):1249-1258.
Horstmann N, Tran CN, Brumlow C, DebRoy S, Yao H, Nogueras Gonzalez G, Makthal N, Kumaraswami M, Shelburne SA: PLoS Pathog 2018, 14(10): e1007354.
Hosry J, Angelidakis G, Kaseb A, Jiang Y, Torres HA: Clin Infect Dis 2018, 67(10):1635-1636.
Hosry J, Miranda RN, Samaniego F, Economides MP, Torres HA: Int J Cancer 2018, 142(5):940-948.
Hwang JP, Ahmed S, Ariza-Heredia EJ, Duan Z, Zhao H, Schmeler KM, Ramondetta L, Parker SL, Suarez-Almazor ME, Ferrajoli A et al: Biol Blood Marrow Transplant 2018, 24(5):1094-1098.
Hwang JP, Lok AS, Fisch MJ, Cantor SB, Barbo A, Lin HY, Foreman JT, Vierling JM, Torres HA, Granwehr BP et al: J Clin Oncol 2018, 36(10):959-967.
Hwang JP, Torres HA: Curr Opin Infect Dis 2018, 31(6):535-541.
Kasembeli MM, Bharadwaj U, Robinson P, Tweardy DJ: Int J Mol Sci 2018, 19(8).
Lacourt TE, Kavelaars A, Ohanian M, Shah ND, Shelburne SA, Futreal A, Kontoyiannis DP, Heijnen CJ: Oncotarget 2018, 9(58):31244-31252.
Leal SM, Jr., Popowitch EB, Levinson KJ, John TM, Lehman B, Rios MB, Gilligan PH, Miller MB: J Clin Microbiol 2018, 56(6).
Li X, Arias CA, Aitken SL, Galloway Pe?a J, Panesso D, Chang M, Diaz L, Rios R, Numan Y, Ghaoui S et al: Clin Infect Dis 2018, 67(3):398-406.
Lu H, Lok AS, Warneke CL, Ahmed S, Torres HA, Martinez F, Suarez-Almazor ME, Foreman JT, Ferrajoli A, Hwang JP: Lancet Haematol 2018, 5(10): e474-e478.
Magira EE, Jiang Y, Economides M, Tarrand J, Kontoyiannis DP: Mycoses 2018, 61(11):861-867.
Magira EE, Jiang Y, Kontoyiannis DP: Med Mycol 2018.
Mah A, Viola GM, Ariza Heredia E, Rezvani K, Kebriaei P, Bhatti MM, Han X, Shpall EJ, Mulanovich VE: Transpl Infect Dis 2018, 20(4): e12899.
Mak LY, Cruz-Ram��n V, Chinchilla-L��pez P, Torres HA, LoConte NK, Rice JP, Foxhall LE, Sturgis EM, Merrill JK, Bailey HH et al: Am Soc Clin Oncol Educ Book 2018, 38:262-279.
Muftuoglu M, Olson A, Marin D, Ahmed S, Mulanovich V, Tummala S, Chi TL, Ferrajoli A, Kaur I, Li L et al: N Engl J Med 2018, 379(15):1443-1451.
Mulanovich V, Kontoyiannis DP: Leuk Lymphoma 2018, 59(6):1284-1291.
Raad, II, Chaftari AM, Dib RW, Graviss EA, Hachem R: Infect Control Hosp Epidemiol 2018, 39(10):1230-1236.
Raad, II, Chaftari AM, Torres HA, Ayoub EM, Narouz LI, Bartek J, Hachem R: C World J Hepatol 2018, 10(9):549-557.
Rajan A, Vela L, Zeng XL, Yu X, Shroyer N, Blutt SE, Poole NM, Carlin LG, Nataro JP, Estes MK et al: mBio 2018, 9(1).
Rice TW, Brock PA, Gonzalez C, Merriman KW, Shelal Z, Bazerbashi H, Granwehr BP: Acute Med 2018, 17(2):91-95.
Rolston KVI, Reitzel R, Vargas-Cruz N, Shelburne SA, Raad, II, Prince RA: Diagn Microbiol Infect Dis 2018, 91(4):351-353.
Sheshadri A, Shah DP, Godoy M, Erasmus JJ, Song J, Li L, Evans SE, Chemaly RF, Dickey BF, Ost DE: PLoS One 2018, 13(5): e0197418.
Sipsas NV, Gamaletsou MN, Anastasopoulou A, Kontoyiannis DP: J Fungi (Basel) 2018, 4(3).
Tatara AM, Wurster S, Lockworth CR, Albert ND, Walsh TJ, Mikos AG, Eisenhoffer GT, Kontoyiannis DP: Antimicrob Agents Chemother 2018, 62(11).
Vakil E, Sheshadri A, Faiz SA, Shah DP, Zhu Y, Li L, Kmeid J, Azzi J, Balagani A, Bashoura L et al: Transpl Infect Dis 2018, 20(6): e12994.
Vilar-Compte D, Shah DP, Vanichanan J, Cornejo-Juarez P, Garcia-Horton A, Volkow P, Chemaly RF: J Med Virol 2018, 90(1):50-60.
Wilson Dib R, Chaftari AM, Hachem RY, Yuan Y, Dandachi D, Raad, II: Open Forum Infect Dis 2018, 5(10): ofy249.
Yalamanchili H, Dandachi D, Okhuysen PC: Gastroenterol Hepatol (N Y) 2018, 14(11):646-652.
Ye X, Iwuchukwu OP, Avadhanula V, Aideyan LO, McBride TJ, Ferlic-Stark LL, Patel KD, Piedra FA, Shah DP, Chemaly RF et al: J Infect Dis 2018, 217(8):1247-1256.

2019

Abers MS, Lionakis MS, Kontoyiannis DP: Trends Mol Med 2019, 25(12):1080-1093.
Abou Dalle I, Bannon SA, Patel KP, Routbort MJ, Cortes JE, Ferrajoli A, Kontoyiannis DP, Wang SA, DiNardo CD: JCO Precis Oncol 2019, 3.
Abu-Sbeih H, Choi K, Tran CN, Wang X, Lum P, Shuttlesworth G, Stroehlein JR, Okhuysen PC, Wang Y: Eur J Gastroenterol Hepatol 2019, 31(1):128-134.
Abu-Sbeih H, Herrera LN, Tang T, Altan M, Chaftari AM, Okhuysen PC, Jenq RR, Wang Y: J Immunother Cancer 2019, 7(1):352.
Abu-Sbeih H, Herrera LN, Tang T, Altan M, Chaftari AP, Okhuysen PC, Jenq RR, Wang Y: J Immunother Cancer 2019, 7(1):242.
Abu-Sbeih H, Tang T, Ali FS, Luo W, Neelapu SS, Westin JR, Okhuysen PC, Foo WC, Curry JL, Richards DM et al: Am J Clin Oncol 2019, 42(10):789-796.
Alfayez M, Burger JA, Kadia T, Xu TH, Szvalb AD, Pemmaraju N: Leuk Lymphoma 2019, 60(13):3341-3342.
Alfayez M, Wang SA, Bannon SA, Kontoyiannis DP, Kornblau SM, Orange JS, Mace EM, DiNardo CD: Leuk Lymphoma 2019, 60(8):2025-2033.
Benanti GE, Brown ART, Shigle TL, Tarrand JJ, Bhatti MM, McDaneld PM, Shelburne SA, Aitken SL: Antimicrob Agents Chemother 2019, 63(2).
Bharadwaj U, Eckols TK, Xu X, Kasembeli MM, Chen Y, Adachi M, Song Y, Mo Q, Lai SY, Tweardy DJ: Oncotarget 2019, 10(16):1603.
Chaftari AM, Viola GM, Rosenblatt J, Hachem R, Raad I: Infect Control Hosp Epidemiol 2019, 40(9):1036-1045.
Chemaly RF, Chou S, Einsele H, Griffiths P, Avery R, Razonable RR, Mullane KM, Kotton C, Lundgren J, Komatsu TE et al: Clin Infect Dis 2019, 68(8):1420-1426.
Chemaly RF, Hill JA, Voigt S, Peggs KS: Antiviral Res 2019, 163:50-58.
Chikley A, Ben-Ami R, Kontoyiannis DP: J Fungi (Basel) 2019, 5(3).
Chow NA, Toda M, Pennington AF, Anassi E, Atmar RL, Cox-Ganser JM, Da Silva J, Garcia B, Kontoyiannis DP, Ostrosky-Zeichner L et al: MMWR Morb Mortal Wkly Rep 2019, 68(21):469-473.
Cornely OA, Hoenigl M, Lass-Fl?rl C, Chen SC, Kontoyiannis DP, Morrissey CO, Thompson GR, 3rd: Mycoses 2019, 62(9):716-729.
Dailey Garnes NJM, Ragoonanan D, Aboulhosn A: Curr Opin Infect Dis 2019, 32(6):591-600.
De la Hoz A, Foolad F, Gallegos C, Kornblau S, Kontoyiannis DP: Bone Marrow Transplant 2019, 54(5):749-751.
Debiane L, Reitzel R, Rosenblatt J, Gagea M, Chavez MA, Adachi R, Grosu HB, Sheshadri A, Hill LR, Raad I et al: Respiration 2019, 98(1):60-69.
DiPippo AJ, Kontoyiannis DP: Clin Infect Dis 2019, 69(9):1624-1627.
DiPippo AJ, Rausch CR, Kontoyiannis DP: Mycoses 2019, 62(1):81-86.
El Haddad L, Ariza-Heredia E, Shah DP, Jiang Y, Blanchard T, Ghantoji SS, El Chaer F, El-Haddad D, Prayag A, Nesher L et al: J Infect Dis 2019, 219(6):898-907.
El Haddad L, Harb CP, Gebara MA, Stibich MA, Chemaly RF: Clin Infect Dis 2019, 69(1):167-178.
Fares J, Khalil M, Chaftari AM, Hachem R, Jiang Y, Kantarjian HM, Raad, II: Open Forum Infect Dis 2019, 6(10): ofz357.
Flores AR, Chase McNeil J, Shah B, Van Beneden C, Shelburne SA: J Pediatric Infect Dis Soc 2019, 8(3):244-250.
Foolad F, Aitken SL, Shigle TL, Prayag A, Ghantoji S, Ariza-Heredia E, Chemaly RF: Clin Infect Dis 2019, 68(10):1641-1649.
Galloway-Pe?a JR, Peterson CB, Malik F, Sahasrabhojane PV, Shah DP, Brumlow CE, Carlin LG, Chemaly RF, Im JS, Rondon G et al: Open Forum Infect Dis 2019, 6(5): ofz173.
Ghobadi A, Milton DR, Gowda L, Rondon G, Chemaly RF, Hamdi A, Alousi A, Afrough A, Oran B, Ciurea S et al: Curr Res Transl Med 2019, 67(2):51-55.
Hachem R, Batista MV, Kanj SS, El Zein S, Haddad S, Jiang Y, Mori N, Vanderson R, Chaftari AM, Raad I: Mediterr J Hematol Infect Dis 2019, 11(1): e2019003.
Hwang JP, LoConte NK, Rice JP, Foxhall LE, Sturgis EM, Merrill JK, Torres HA, Bailey HH: J Oncol Pract 2019, 15(12):629-637.
Kettner NM, Vijayaraghavan S, Durak MG, Bui T, Kohansal M, Ha MJ, Liu B, Rao X, Wang J, Yi M et al: Clin Cancer Res 2019, 25(13):3996-4013.
Khawaja F, Batista MV, El Haddad L, Chemaly RF: Curr Opin Infect Dis 2019, 32(6):565-574.
Khawaja F, Chemaly RF: Haematologica 2019, 104(7):1322-1331.
Kmeid J, Kulkarni PA, Batista MV, El Chaer F, Prayag A, Ariza-Heredia EJ, Mulanovich VE, Chemaly RF: BMC Infect Dis 2019, 19(1):934.
Kontoyiannis DP: Future Microbiol 2019, 14:1083-1085.
Kontoyiannis DP, Shah EC, Wurster S, Aitken SL, Graviss L, Raad, II, Chemaly RF: Open Forum Infect Dis 2019, 6(4): ofz138.
Kontoyiannis PD, Koons GL, Hicklen RS, Mikos AG, Kontoyiannis DP: Open Forum Infect Dis 2019, 6(10): ofz385.
Kuhlmann FM, Martin J, Hazen TH, Vickers TJ, Pashos M, Okhuysen PC, G��mez-Duarte OG, Cebelinski E, Boxrud D, Del Canto F et al: PLoS Negl Trop Dis 2019, 13(11): e0007825.
Lamoth F, Kontoyiannis DP: Antimicrob Agents Chemother 2019, 63(11).
Lewis RE, Kontoyiannis DP, Viale P, Sarpong EM: Antimicrob Agents Chemother 2019, 63(12).
Lewis RE, Wurster S, Beyda ND, Albert ND, Kontoyiannis DP: Diagn Microbiol Infect Dis 2019, 95(3):114861.
Magira EE, Chemaly RF, Jiang Y, Tarrand J, Kontoyiannis DP: Corrigendum: Open Forum Infect Dis 2019, 6(11): ofz458.
Magira EE, Chemaly RF, Jiang Y, Tarrand J, Kontoyiannis DP: Open Forum Infect Dis 2019, 6(7): ofz247.
Malek AE, Fares JE, Raad, II, Ericsson C: IDCases 2019, 18: e00630.
Marty FM, Winston DJ, Chemaly RF, Mullane KM, Shore TB, Papanicolaou GA, Chittick G, Brundage TM, Wilson C, Morrison ME et al: Biol Blood Marrow Transplant 2019, 25(2):369-381.
Mason MJ, McDaneld PM, Musick WL, Kontoyiannis DP: Antimicrob Agents Chemother 2019, 63(5).
Mullane KM, Winston DJ, Nooka A, Morris MI, Stiff P, Dugan MJ, Holland H, Gregg K, Adachi JA, Pergam SA et al: Clin Infect Dis 2019, 68(2):196-203.
Mu?oz NM, Minhaj AA, Dupuis CJ, Ensor JE, Golardi N, Jaso JM, Dixon KA, Figueira TA, Galloway-Pe?a JR, Hill L et al: Clin Orthop Relat Res 2019, 477(10):2367-2377.
Narula N, Lillemoe HA, Caudle AS, Chemaly RF, Anderson JJ, Segal C, Porter CA, Swisher SG, Levenback CF, Aloia TA: Jt Comm J Qual Patient Saf 2019, 45(10):686-693.
Pergam SA, Englund JA, Kamboj M, Gans HA, Young JH, Hill JA, Savani B, Chemaly RF, Dadwal SS, Storek J et al: Biol Blood Marrow Transplant 2019, 25(11): e321-e330.
Potenza L, Chitasombat MN, Klimko N, Bettelli F, Dragonetti G, Del Principe MI, Nucci M, Busca A, Fracchiolla N, Scium�� M et al: Mycoses 2019, 62(3):223-229.
Rolston KVI, Jamal M, Nesher L, Raad I, Rice SA, Rybak MJ, Prince RA: J Glob Antimicrob Resist 2019, 17:16-18.
Rosenblatt J, Vargas-Cruz N, Reitzel RA, Raad, II: Antimicrob Agents Chemother 2019, 63(5).
Sheshadri A, Chemaly RF, Alousi AM, Shah PK, Rondon G, Bashoura L, Kmeid J, Azzi J, Blanco DW, Kaous M et al: Biol Blood Marrow Transplant 2019, 25(4):800-809.
Sheshadri A, Godoy M, Erasmus JJ, Gruschkus S, Hasan A, Evans SE, Barreda-Garcia J, Chemaly RF, Dickey B, Ost D: BMJ Open Respir Res 2019, 6(1): e000471.
Sheshadri A, Karimipour M, Vakil E, Bashoura L, Godoy M, Arain MH, Evans SE, Dickey BF, Ost DE, Chemaly RF et al: Transpl Infect Dis 2019, 21(4): e13105.
Stanzani M, Vianelli N, Cavo M, Kontoyiannis DP, Lewis RE: J Infect 2019, 78(6):484-490.
Strati P, Gabutti C, Thompson PA, Kontoyiannis DP, Ferrajoli A: Leuk Lymphoma 2019, 60(2):535-537.
Szvalb AD, El Haddad H, Rolston KV, Sabir SH, Jiang Y, Raad, II, Viola GM: Infection 2019, 47(2):239-245.
Szvalb AD, Kontoyiannis DP: Mycoses 2019, 62(9):847-853.
Szvalb AD, Rolston KV, Mori N, Tarrand JJ, Mulanovich VE: J Infect 2019, 78(1):48-53.
Tahtouh R, Wardi L, Sarkis R, Hachem R, Raad I, El Zein N, Hilal G: Cell Mol Biol (Noisy-le-grand) 2019, 65(7):26-33.
Taremi M, Artau A, Foolad F, Berlin S, White C, Jiang Y, Raad I, Adachi J: J Allergy Clin Immunol Pract 2019, 7(7):2185-2191.e2181.
Tatara AM, Watson E, Albert ND, Kontoyiannis PD, Kontoyiannis DP, Mikos AG: J Biomed Mater Res A 2019, 107(9):1867-1874.
Torres HA, Economides MP, Angelidakis G, Hosry J, Kyvernitakis A, Mahale P, Jiang Y, Miller E, Blechacz B, Naing A et al: Am J Gastroenterol 2019, 114(2):250-257.
Torres HA, Pundhir P, Mallet V: Gastroenterology 2019, 157(4):909-916.
Tran TT, Mishra NN, Seepersaud R, Diaz L, Rios R, Dinh AQ, Garcia-de-la-Maria C, Rybak MJ, Miro JM, Shelburne SA et al: Antimicrob Agents Chemother 2019, 63(2).
Vargas-Cruz N, Reitzel RA, Rosenblatt J, Chaftari AM, Wilson Dib R, Hachem R, Kontoyiannis DP, Raad, II: Antimicrob Agents Chemother 2019, 63(7).
Vargas-Cruz N, Rosenblatt J, Reitzel RA, Chaftari AM, Hachem R, Raad I: Biomed Res Int 2019, 2019:2869039.
Viola GM, Rolston KV, Butler C, Selber J, Reece G, Clemens M, Villa M, Raad, II, Baumann D: Plast Reconstr Surg Glob Open 2019, 7(7): e2342.
Walsh TJ, Hospenthal DR, Petraitis V, Kontoyiannis DP: J Fungi (Basel) 2019, 5(3).
Wang EW, Bhatti M, Cantu S, Okhuysen PC: Open Forum Infect Dis 2019, 6(4): ofz116.
Wang Q, Kontoyiannis DP, Li R, Chen W, Bu D, Liu W: J Clin Microbiol 2019, 57(9).
Wurster S, Bandi A, Beyda ND, Albert ND, Raman NM, Raad, II, Kontoyiannis DP: J Antimicrob Chemother 2019, 74(7):1904-1910.
Wurster S, Kumaresan PR, Albert ND, Hauser PJ, Lewis RE, Kontoyiannis DP: mBio 2019, 10(3).
Wurster S, Lewis RE, Albert ND, Kontoyiannis DP: Antimicrob Agents Chemother 2019, 63(2).
Ye X, Iwuchukwu OP, Avadhanula V, Aideyan LO, McBride TJ, Ferlic-Stark LL, Patel KD, Piedra FA, Shah DP, Chemaly RF et al: Front Immunol 2019, 10:706.
Zhang H, Tan J, Kontoyiannis DP, Zhou Y, Liu W, Zhu P, Shi X, Wan Z, Li R, Liu W: Diagn Microbiol Infect Dis 2019, 95(2):166-170.
Zhang X, Browman G, Siu W, Basen-Engquist KM, Hanash SM, Hoffman KL, Okhuysen PC, Scheet P, Petrosino JF, Kopetz S et al: BMC Cancer 2019, 19(1):1233.

2020

Abu-Sbeih H, Ali FS, Chen E, Mallepally N, Luo W, Lu Y, Foo WC, Qiao W, Okhuysen PC, Adachi JA et al: Dis Colon Rectum 2020, 63(3):381-388.
Abudayyeh A, Lin H, Abdelrahim M, Rondon G, Andersson BS, Martinez CS, Page VD, Tarrand JJ, Kontoyiannis DP, Marin D et al: Transpl Infect Dis 2020, 22(5): e13395.
Al-Shamsi HO, Alhazzani W, Alhuraiji A, Coomes EA, Chemaly RF, Almuhanna M, Wolff RA, Ibrahim NK, Chua MLK, Hotte SJ et al: Oncologist 2020, 25(6): e936-e945.
Aldoss I, La Rosa C, Baden LR, Longmate J, Ariza-Heredia EJ, Rida WN, Lingaraju CR, Zhou Q, Martinez J, Kaltcheva T et al: Ann Intern Med 2020, 172(5):306-316.
Algwaiz G, Aljurf M, Koh M, Horowitz MM, Ljungman P, Weisdorf D, Saber W, Kodera Y, Szer J, Jawdat D et al: Biol Blood Marrow Transplant 2020, 26(12):2181-2189.
Alvarez-Cardona JJ, Whited LK, Chemaly RF: Future Microbiol 2020, 15:389-400.
Amenta EM, Spallone A, Rodriguez-Barradas MC, El Sahly HM, Atmar RL, Kulkarni PA: Open Forum Infect Dis 2020, 7(12): ofaa509.
Anastasopoulou A, DiPippo AJ, Kontoyiannis DP: Mycoses 2020, 63(8):787-793.
Angelidakis G, Krishnan S, Cabrera NL, Jiang Y, Pushparaji B, Kaseb A, Torres HA: Hepatology 2020, 72(2):775-777.
Angelidakis G, Mahale P, Jonasch E, Jiang Y, Torres HA: Semin Oncol 2020, 47(2-3):165-167.
Arora S, Li X, Hillhouse A, Konganti K, Little SV, Lawhon SD, Threadgill D, Shelburne S, Hook M: mBio 2020, 11(1).
Bajaj N, Granwehr BP, Hanna EY, Chambers MS: Head Neck 2020, 42(7):1543-1547.
Bharadwaj U, Kasembeli MM, Robinson P, Tweardy DJ: Pharmacol Rev 2020, 72(2):486-526.
Cabrera NL, Malek AE, Shelburne S, Taremi M, Awadh H, Francisco D, Robins A, Jabbour E, Chemaly RF: Infection 2020, 48(3):477-481.
Chakravarti D, Hu B, Mao X, Rashid A, Li J, Li J, Liao WT, Whitley EM, Dey P, Hou P et al: Nat Commun 2020, 11(1):4766.
Chemaly RF, Dadwal SS, Bergeron A, Ljungman P, Kim YJ, Cheng GS, Pipavath SN, Limaye AP, Blanchard E, Winston DJ et al: Clin Infect Dis 2020, 71(11):2777-2786.
Chemaly RF, El Haddad L, Winston DJ, Rowley SD, Mulane KM, Chandrasekar P, Avery RK, Hari P, Peggs KS, Kumar D et al: Clin Infect Dis 2020, 71(9):2365-2374.
Coomes EA, Al-Shamsi HO, Meyers BM, Alhazzani W, Alhuraiji A, Chemaly RF, Almuhanna M, Wolff RA, Ibrahim NK, Chua MLK et al: Oncologist 2020, 25(9): e1426-e1427.
Dib RW, Khalil M, Fares J, Hachem RY, Jiang Y, Dandachi D, Chaftari AM, Raad, II: J Hosp Infect 2020, 104(3):358-364.
Dipippo AJ, Kontoyiannis DP: Clin Infect Dis 2020, 71(2):467-468.
Donnelly JP, Chen SC, Kauffman CA, Steinbach WJ, Baddley JW, Verweij PE, Clancy CJ, Wingard JR, Lockhart SR, Groll AH et al: Clin Infect Dis 2020, 71(6):1367-1376.
El Haddad L, Ghantoji SS, Park AK, Batista MV, Schelfhout J, Hachem J, Lobo Y, Jiang Y, Rondon G, Champlin R et al: J Med Virol 2020, 92(1):86-95.
ElGohary GM, Hashmi S, Styczynski J, Kharfan-Dabaja MA, Alblooshi RM, de la C��mara R, Mohmed S, Alshaibani A, Cesaro S, Abd El-Aziz N et al: Hematol Oncol Stem Cell Ther 2020.
Fern��ndez-Cruz A, Lewis RE, Kontoyiannis DP: Clin Infect Dis 2020, 71(3):685-692.
Flores AR, Shelburne SA: Clin Infect Dis 2020, 70(7):1482-1483.
Frei M, Aitken SL, Jain N, Thompson P, Wierda W, Kontoyiannis DP, DiPippo AJ: Leuk Lymphoma 2020, 61(10):2488-2491.
Frigeni M, Besson C, Visco C, Fontaine H, Goldaniga M, Visentini M, Pulsoni A, Torres HA, Peveling-Oberhag J, Rossotti R et al: Leukemia 2020, 34(5):1462-1466.
Fuentes S, Hahn M, Chilcote K, Chemaly RF, Shah DP, Ye X, Avadhanula V, Piedra PA, Golding H, Khurana S: J Infect Dis 2020, 221(4):636-646.
Galloway-Pe?a JR, Kontoyiannis DP: PLoS Pathog 2020, 16(4): e1008353.
Galloway-Pe?a JR, Shi Y, Peterson CB, Sahasrabhojane P, Gopalakrishnan V, Brumlow CE, Daver NG, Alfayez M, Boddu PC, Khan MAW et al: Clin Infect Dis 2020, 71(1):63-71.
Garcia-Vidal C, Lewis RE, Kontoyiannis DP: J Antimicrob Chemother 2020, 75(11):3096-3098.
G��mez-Sandoval JN, Okhuysen P, Mondrag��n-Flores R, Escalona-Monta?o AR, Aguirre-Garc��a MM: Acta Parasitol 2020, 65(3):704-715.
Hanage WP, Shelburne SA: Clin Infect Dis 2020, 71(1):205-206.
Hosry J, Miranda RN, Samaniego F, Angelidakis G, Torres HA: Hematol Oncol 2020, 38(3):301-308.
John TM, Malek AE, Mulanovich VE, Adachi JA, Raad, II, Hamilton AR, Shpall EJ, Rezvani K, Aitken SL, Jain N et al: Mayo Clin Proc 2020, 95(9):2038 2040.
Johnson MD, Lewis RE, Dodds Ashley ES, Ostrosky-Zeichner L, Zaoutis T, Thompson GR, Andes DR, Walsh TJ, Pappas PG, Cornely OA et al: J Infect Dis 2020, 222(Suppl 3): S175-s198.
Khalil M, Karimzad K, Durand JB, Malek AE, Raad, II, Viola GM: Open Forum Infect Dis 2020, 7(11): ofaa433.
Kim J, Greenberg DE, Pifer R, Jiang S, Xiao G, Shelburne SA, Koh A, Xie Y, Zhan X: PLoS Comput Biol 2020, 16(1): e1007511.
Kim ST, Sheshadri A, Shannon V, Kontoyiannis DP, Kantarjian H, Garcia-Manero G, Ravandi F, Im JS, Boddu P, Bashoura L et al: Front Immunol 2020, 11:590494.
Koehler P, Denis B, Denning DW, Gangneux JP, Hoenigl M, Kontoyiannis DP, Krause R, Lagrou K, Lass-Fl?rl C, Maertens J et al: Mycoses 2020, 63(6):566-572.
Lewis RE, Kontoyiannis DP: Lancet Infect Dis 2020, 20(2):164.
Lewis RE, Kontoyiannis DP: Clin Infect Dis 2020, 71(7):1802-1803.
Ljungman P, Schmitt M, Marty FM, Maertens J, Chemaly RF, Kartsonis NA, Butterton JR, Wan H, Teal VL, Sarratt K et al: Clin Infect Dis 2020, 70(8):1525-1533.
Malek A, Khalil M, Hachem R, Chaftari AM, Fares J, Jiang Y, Kontoyiannis DP, Fossella F, Chaftari P, Mulanovich V et al: Clin Infect Dis 2020.
Malek AE, Granwehr BP, Kontoyiannis DP: IDCases 2020, 21: e00864.
Malek AE, Gutierrez C, Mulanovich VE, Botdorf J, Chemaly RF, Shah S, McCall BM, Melancon JT, McConn KK, Borjan J et al: Mediterr J Hematol Infect Dis 2020, 12(1): e2020044.
Malek AE, Nieto Y, Szvalb AD, Siddiqui S, Shafi MA, Hwang JP, Raad, II, Torres HA: Clin Lymphoma Myeloma Leuk 2020, 20(3): e124-e127.
Malek AE, Raad, II: Expert Rev Anti Infect Ther 2020, 18(6):531-538.
Malek AE, Raad, II, Jabbour E: Lancet 2020, 396(10257):1066-1067.
Malek AE, Skaff Y, Mulanovich VE: Infection 2020, 48(5):811.
Malek AE, Skaff Y, Mulanovich VE: Infection 2020, 48(5):809-810.
Malek AE, Viola GM, Seiler GT, Szvalb AD: Infection 2020, 48(3):487-488.
Manasanch EE, Mulanovich V, Manzano JG, Gaeta MS, Becnel M, Kaufman GP, Lee HC, Amini B, Thomas SK, Iyer SP et al: Leuk Lymphoma 2020, 61(11):2763-2766.
Marty FM, Chemaly RF, Mullane KM, Lee DG, Hirsch HH, Small CB, Bergeron A, Shoham S, Ljungman P, Waghmare A et al: Clin Infect Dis 2020, 71(11):2787-2795.
Marty FM, Ljungman PT, Chemaly RF, Wan H, Teal VL, Butterton JR, Yeh WW, Leavitt RY, Badshah CS: Am J Transplant 2020, 20(6):1703-1711.
Minus MB, Wang H, Munoz JO, Stevens AM, Mangubat-Medina AE, Krueger MJ, Liu W, Kasembeli MM, Cooper JC, Kolosov MI et al: Org Biomol Chem 2020, 18(17):3288-3296.
Mitra A, Grossman Biegert GW, Delgado AY, Karpinets TV, Solley TN, Mezzari MP, Yoshida-Court K, Petrosino JF, Mikkelson MD, Lin L et al: Int J Radiat Oncol Biol Phys 2020, 107(1):163-171.
Pappas PG, Boulware DR, Kontoyiannis DP, Miceli MH, Ostrosky-Zeichner L, Spec A, Thompson GR, Chen S, Perfect JR: . Med Mycol 2020, 58(5):569-578.
Pritchard H, Jandhyala D, Hosry J, Angelidakis G, Torres HA: JGH Open 2020, 4(3):541-544.
Puerta-Alcalde P, Champlin R, Kontoyiannis DP: Blood 2020.
Rajan A, Robertson MJ, Carter HE, Poole NM, Clark JR, Green SI, Criss ZK, Zhao B, Karandikar U, Xing Y et al: PLoS Pathog 2020, 16(9): e1008851.
Reitzel RA, Rosenblatt J, Gerges BZ, Jarjour A, Fern��ndez-Cruz A, Raad, II: . JAC Antimicrob Resist 2020, 2(1): dlaa002.
Reitzel RA, Rosenblatt J, Gerges BZ, Vargas-Cruz N, Raad, II: Antimicrob Agents Chemother 2020, 64(4).
Reyes-Gibby CC, Wang J, Zhang L, Peterson CB, Do KA, Jenq RR, Shelburne S, Shah DP, Chambers MS, Hanna EY et al: Cancer 2020, 126(23):5124-5136.
Robinson S, Peterson CB, Sahasrabhojane P, Ajami NJ, Shelburne SA, Kontoyiannis DP, Galloway-Pe?a JR: mSphere 2020, 5(2).
Rolston KVI, Gerges B, Shelburne S, Aitken SL, Raad I, Prince RA: Antimicrob Agents Chemother 2020, 64(5).
Sharma M, Khong H, Fa'ak F, Bentebibel SE, Janssen LME, Chesson BC, Creasy CA, Forget MA, Kahn LMS, Pazdrak B et al: Nat Commun 2020, 11(1):661.
Shelburne SA, Dib RW, Endres BT, Reitzel R, Li X, Kalia A, Sahasrabhojane P, Chaftari AM, Hachem R, Vargas-Cruz NS et al: Clin Microbiol Infect 2020, 26(5): 646.e641-646.e648.
Shigle TL, Handy VW, Chemaly RF: Ther Adv Hematol 2020, 11:2040620720937150.
Spallone A, Hicklen RS, Kontoyiannis DP: Open Forum Infect Dis 2020, 7(7): ofaa247.
Strati P, Varma A, Adkins S, Nastoupil LJ, Westin J, Hagemeister FB, Fowler NH, Lee HJ, Fayad LE, Samaniego F et al: Haematologica 2020.
Szvalb AD, Malek AE, Jiang Y, Bhatti MM, Wurster S, Kontoyiannis DP: J Infect 2020, 81(3):443-451.
Waghmare A, Abidi MZ, Boeckh M, Chemaly RF, Dadwal S, El Boghdadly Z, Kamboj M, Papanicolaou GA, Pergam SA, Shahid Z: Biol Blood Marrow Transplant 2020, 26(11):1983-1994.
Wurster S, Robinson P, Albert ND, Tarrand JJ, Goff M, Swamydas M, Lim JK, Lionakis MS, Kontoyiannis DP: . J Infect Dis 2020, 222(6):989-994.
Wurster S, Sass G, Albert ND, Nazik H, D��ziel E, Stevens DA, Kontoyiannis DP: Virulence 2020, 11(1):1329-1336.
Wurster S, Tatara AM, Albert ND, Ibrahim AS, Heitman J, Lee SC, Shetty AC, McCracken C, Graf KT, Mikos AG et al: mBio 2020, 11(3).
Yang X, Shi X, Chen W, Zhou Y, Lionakis MS, Kontoyiannis DP, Liu W: . Med Mycol Case Rep 2020, 29:5-7.
Ye X, Cabral de Rezende W, Iwuchukwu OP, Avadhanula V, Ferlic-Stark LL, Patel KD, Piedra FA, Shah DP, Chemaly RF, Piedra PA: Vaccines (Basel) 2020, 8(2).
Yibirin M, Pritchard H, Torres HA: Diagn Microbiol Infect Dis 2020, 97(4):115057.
Zhang L, Chen Z, Wang Y, Tweardy DJ, Mitch WE: Am J Physiol Endocrinol Metab 2020, 318(5): E625-e635.
Zhang L, Wang Y, Dong Y, Chen Z, Eckols TK, Kasembeli MM, Tweardy DJ, Mitch WE: Am J Physiol Renal Physiol 2020, 319(1): F84-f92.

2021

Aitken SL, Sahasrabhojane PV, Kontoyiannis DP, Savidge TC, Arias CA, Ajami NJ, Shelburne SA, Galloway-Pe?a JR: Clin Infect Dis 2021, 72(9):1507-1513.
Alsumali A, Chemaly RF, Graham J, Jiang Y, Merchant S, Miles L, Schelfhout J, Yang J, Tang Y: J Med Virol 2021, 93(6):3786-3794.
Ariza-Heredia EJ, Frenzel E, Cantu S, Carlson M, Thomas G, Khawaja F, Raad, II, Chemaly RF: Infect Control Hosp Epidemiol 2021, 42(7):797-802.
Awadh H, Chaftari AM, Khalil M, Fares J, Jiang Y, Deeba R, Ali S, Hachem R, Raad, II: BMC Infect Dis 2021, 21(1):643.
Axell-House DB, Wurster S, Jiang Y, Kyvernitakis A, Lewis RE, Tarrand JJ, Raad, II, Kontoyiannis DP: J Fungi (Basel) 2021, 7(3).
Ben-Ami R, Kontoyiannis DP: Infect Dis Clin North Am 2021, 35(2):279-311.
Bose P, McCue D, Wurster S, Wiederhold NP, Konopleva M, Kadia TM, Borthakur G, Ravandi F, Masarova L, Takahashi K et al: Clin Infect Dis 2021, 72(10):1755-1763.
Carpenter PA, Papanicolaou G, Chemaly RF, Boeckh M, Savani BN: Transplant Cell Ther 2021, 27(2):103-104.
Casadevall A, Kontoyiannis DP, Robert V: mBio 2021, 12(2).
Chamilos G, Lionakis MS, Kontoyiannis DP: Clin Infect Dis 2021, 72(2):351-356.
Chemaly RF: Clin Microbiol Infect 2021.
Chemaly RF, Marty FM, Wolfe CR, Lawrence SJ, Dadwal S, Soave R, Farthing J, Hawley S, Montanez P, Hwang J et al: Clin Infect Dis 2021, 73(3): e773-e781.
Colombo AL, Agnelli C, Kontoyiannis DP: J Antimicrob Chemother 2021, 76(3):543-546.
Dadwal SS, Hohl TM, Fisher CE, Boeckh M, Papanicolaou G, Carpenter PA, Fisher BT, Slavin MA, Kontoyiannis DP: Transplant Cell Ther 2021, 27(3):201-211.
DebRoy S, Aliaga-Tobar V, Galvez G, Arora S, Liang X, Horstmann N, Maracaja-Coutinho V, Latorre M, Hook M, Flores AR et al: Mol Microbiol 2021, 115(6):1207-1228.
DebRoy S, Sanson M, Shah B, Regmi S, Vega LA, Odo C, Sahasrabhojane P, McGeer A, Tyrrell GJ, Fittipaldi N et al: mSystems 2021: e0049521.
El Haddad L, Hanson BM, Arias CA, Ghantoji SS, Harb CP, Stibich M, Chemaly RF: Clin Infect Dis 2021.
Fekkar A, Neofytos D, Nguyen MH, Clancy CJ, Kontoyiannis DP, Lamoth F: Clin Microbiol Infect 2021.
Gans H, Chemaly RF: BMC Infect Dis 2021, 21(1):46.
Gerges BZ, Rosenblatt J, Truong YL, Reitzel RA, Hachem R, Raad, II: Biomed Res Int 2021, 2021:2710484.
Gerges BZ, Rosenblatt J, Truong YL, Reitzel RA, Raad I: Infect Control Hosp Epidemiol 2021:1-15.
Grable C, Yusuf S, Song J, Viola GM, Ulhaq O, Banchs J, Jensen CT, Goel H, Hassan S: Open Heart 2021, 8(2).
Greenbaum U, Klein K, Martinez F, Song J, Thall PF, Ramdial JL, Knape C, Aung FM, Scroggins J, Knopfelmacher A et al: Front Immunol 2021, 12:675679.
Gudiol C, Lewis RE, Strati P, Kontoyiannis DP: Lancet Haematol 2021, 8(3): e216-e228.
Hachem R, Parikh UM, Reitzel R, Rosenblatt J, Kaul A, Vargas-Cruz N, Hill L, Moore L, Meyer J, Chaftari AM et al: Wound Repair Regen 2021.
Handley G, Hasbun R, Okhuysen P: J Clin Virol 2021, 136:104740.
Husni R, Chrabieh R, Dib RW, Vazquez J, Guimaraes T, Fern��ndez A, Khoury R, Asmar L, Khazen G, Samaha N et al: Mediterr J Hematol Infect Dis 2021, 13(1): e2021031.
John TM, Kontoyiannis DP: Chest 2021, 159(4):1687-1688.
John TM, Shrestha NK, Procop GW, Grove D, Leal SM, Jr., Jacob CN, Butler R, Dweik R: PLoS One 2021, 16(8): e0256259.
Karri PV, Torres CA, Dailey Garnes NJ, Ronen S, Khawaja F, Bhatti MM, Hosing C, Patel AB: Dermatol Online J 2021, 27(6).
Kaseb AO, Mohamed YI, Malek AE, Raad, II, Altameemi L, Li D, Kaseb OA, Kaseb SA, Selim A, Ma Q: Pathogens 2021, 10(3).
Kasembeli MM, Singhmar P, Ma J, Edralin J, Tang Y, Adams C, 3rd, Heijnen CJ, Kavelaars A, Tweardy DJ: Biochem Pharmacol 2021, 192:114688.
Kondapi DS, Ramani S, Estes MK, Atmar RL, Okhuysen PC: Open Forum Infect Dis 2021, 8(6): ofab126.
Kong R, Bharadwaj U, Eckols TK, Kolosov M, Wu H, Cruz-Pavlovich FJS, Shaw A, Ifelayo OI, Zhao H, Kasembeli MM et al: Pharmacol Res 2021, 169:105637.
Korompoki E, Gavriatopoulou M, Hicklen RS, Ntanasis-Stathopoulos I, Kastritis E, Fotiou D, Stamatelopoulos K, Terpos E, Kotanidou A, Hagberg CA et al: J Infect 2021, 83(1):1-16.
Korompoki E, Gavriatopoulou M, Kontoyiannis DP: JAMA Oncol 2021, 7(8):1113-1114.
Lamoth F, Lewis RE, Walsh TJ, Kontoyiannis DP: (IAPA). J Infect Dis 2021.
Lass-Fl?rl C, Dietl AM, Kontoyiannis DP, Brock M: Clin Microbiol Rev 2021: e0031120.
Lockhart SR, Bialek R, Kibbler CC, Cuenca-Estrella M, Jensen HE, Kontoyiannis DP: Clin Infect Dis 2021, 72(Suppl 2): S109-s113.
Ma W, Gong Z, Abu-Sbeih H, Peng Y, Peng F, Zou F, Charabaty A, Okhuysen PC, McQuade JL, Altan M et al: Am J Clin Oncol 2021, 44(8):402-408.
Maertens JA, Rahav G, Lee DG, Ponce-de-Le��n A, Ram��rez S��nchez IC, Klimko N, Sonet A, Haider S, Diego V��lez J, Raad I et al: Lancet 2021, 397(10273):499-509.
Malek AE, Adachi JA, Mulanovich VE, Sassine J, Raad, II, McConn K, Seiler GT, Dhal U, Khawaja F, Chemaly RF: Transpl Infect Dis 2021: e13606.
Malek AE, Granwehr BP: Int J Antimicrob Agents 2021, 57(1):106168.
Malek AE, Kontoyiannis DP: Mayo Clin Proc 2021, 96(1):257-258.
Marcelin JR, Cort��s-Penfield N, Del Rio C, Desai A, Echenique I, Granwehr B, Lawal F, Kuriakose K, Lee DH, Malinis M et al: Open Forum Infect Dis 2021, 8(2): ofab027.
Mulroney CM, Bilal Abid M, Bashey A, Chemaly RF, Ciurea SO, Chen M, Dandoy CE, Diaz Perez MA, Friend BD, Fuchs E et al: Br J Haematol 2021, 194(1):145-157.
Olson A, Lin R, Marin D, Rafei H, Bdaiwi MH, Thall PF, Basar R, Abudayyeh A, Banerjee P, Aung FM et al: J Clin Oncol 2021, 39(24):2710-2719.
Olvera A, Carter H, Rajan A, Carlin LG, Yu X, Zeng XL, Shelburne S, Bhatti M, Blutt SE, Shroyer NF et al: Clin Infect Dis 2021, 72(10): e620-e629.
Ong DSY, Fragkou PC, Schweitzer VA, Chemaly RF, Moschopoulos CD, Skevaki C: Clin Microbiol Infect 2021, 27(7):981-986.
P��rez-Jacoiste As��n MA, L��pez-Medrano F, Fern��ndez-Ruiz M, Silva JT, San Juan R, Kontoyiannis DP, Aguado JM: Am J Transplant 2021, 21(2):703-716.
Pritchard H, Hwang JP, Angelidakis G, Yibirin M, Wang L, Miller E, Torres HA: J Viral Hepat 2021, 28(5):844-848.
Pundhir P, Roach LR, Bartek JR, Trask RP, Yibirin M, Guevara EY, Granwehr BP, Swalwell CR, Torres HA: Clin Microbiol Infect 2021.
Ragoonanan D, Khazal SJ, Abdel-Azim H, McCall D, Cuglievan B, Tambaro FP, Ahmad AH, Rowan CM, Gutierrez C, Schadler K et al: Nat Rev Clin Oncol 2021, 18(7):435-453.
Ragoonanan D, Khazal SJ, Mejia R, Ewing L, Durand JB, Bashoura L, Tayar J, Dailey Garnes N, Petropoulos D, Tewari P et al: Front Oncol 2021, 11:625707.
Sanson MA, Vega LA, Shah B, Regmi S, Cubria MB, Horstmann N, Shelburne SA, 3rd, Flores AR: Infect Immun 2021: Iai0021521.
Sassine J, Khawaja F, Shigle TL, Handy V, Foolad F, Aitken S, Jiang Y, Champlin R, Shpall E, Rezvani K et al: Clin Infect Dis 2021.
Sassine J, Kontoyiannis DP: Am J Med 2021, 134(7):860-862.
Satlin MJ, Weissman SJ, Carpenter PA, Seo SK, Shelburne SA: Transplant Cell Ther 2021, 27(2):108-114.
Shah S, Shelburne S: Infect Dis Clin North Am 2021, 35(1):199-217.
Shropshire WC, Aitken SL, Pifer R, Kim J, Bhatti MM, Li X, Kalia A, Galloway-Pe?a J, Sahasrabhojane P, Arias CA et al: . J Antimicrob Chemother 2021, 76(2):385-395.
Simmons SE, Carrion R, Alfson KJ, Staples HM, Jinadatha C, Jarvis WR, Sampathkumar P, Chemaly RF, Khawaja F, Povroznik M et al: Infect Control Hosp Epidemiol 2021, 42(2):127-130.
Spallone A, Schwartz IS: Infect Dis Clin North Am 2021, 35(2):261-277.
Torres HA, Lok AS, Suarez-Almazor ME, Warneke CL, Kaseb A, Miller E, Sturgis EM, Foreman JT, Angelidakis G, Ahmed S et al: Support Care Cancer 2021, 29(1):97 105.
Viola GM, Malek AE, Rosen LB, DiNardo AR, Nishiguchi T, Okhuysen PC, Holland SM, Kontoyiannis DP: Mycoses 2021, 64(6):576-582.
Wurster S, Lyos S, Albert ND, Kontoyiannis DP: Med Mycol 2021, 59(1):102-105.
Wurster S, Ruiz OE, Samms KM, Tatara AM, Albert ND, Kahan PH, Nguyen AT, Mikos AG, Kontoyiannis DP, Eisenhoffer GT: Cell Rep 2021, 34(12):108896.
Ye X, Iwuchukwu OP, Avadhanula V, Aideyan LO, McBride TJ, Henke DM, Patel KD, Piedra FA, Angelo LS, Shah DP et al: Viruses 2021, 13(6).

Why This Program

In addition to gaining unparalleled education and training experience, MD Anderson trainees have access to exceptional resources and benefits to help them build meaningful careers and lead fulfilling lives.

Institutional benefits and support

GME trainees�� salary stipends are updated every year based on the ACGME��s recommendations, and because our trainees are considered workforce members, they also enjoy MD Anderson��s employee benefits, including health insurance, retirement planning, disability insurance and six weeks of parental leave.

Our GME House Staff Senate offers trainees the opportunity to experience a leadership role in a medical field career, and the institution��s Academic Mentoring Council provides avenues to secure tailored academic mentoring from faculty. Our GME trainees benefit from the extensive support offered to our research trainees, too; they are invited to participate in grant application workshops, apply for pilot grants to support their research ideas and receive monetary awards for securing extramural grant funding.

Trainee wellness is also of utmost importance at MD Anderson.

Our trainees have access to MD Anderson��s , fitness center and other wellness resources provided by the institution. Additionally, our Graduate Medical Education Committee (GMEC), which provides oversight of our accredited programs, regularly assess our trainees�� needs and implements various initiatives, such as providing free call meals and discounted parking to GME House Staff, to address those gaps. The committee even has a subcommittee entirely dedicated to supporting the wellness of our trainees.

Our efforts to ensure a welcoming and supportive education and training experience have been commended nationally. In 2023, the Office of Graduate Medical Education received the , a prestigious national award that recognizes our institution for its respectful and supportive environment for delivering medical education and patient care.

Beyond MD Anderson

MD Anderson��s location has many benefits, too. Our main campus is nestled inside the Texas Medical Center, the world��s largest medical center which boasts about 10 million patient encounters each year. Many of our faculty are involved in interorganizational research collaborations, both within the TMC and across the nation, exposing trainees to groundbreaking advancements in medical care in real time.

Most importantly, the city of Houston is a great place to call home and raise a family. We are one of the most culturally diverse cities in the nation. More than 145 different languages are spoken across the city, placing us behind only New York and Los Angeles. In fact, about 30% of the city��s population speaks a language other than English at home. And, paychecks here stretch farther than most U.S. metro areas, thanks to our low cost of living.

Visit our Why Houston page to learn more about our city��s affordable housing, fine dining, entertainment scene, nationally renowned museums and other great attributes.

�鶹ӳ��